aTyr Pharma (ATYR) Stock: Buy, Sell, or Hold?
ATYR - aTyr Pharma, Inc. Common Stock
$0.43
0.00 (-0.49%)
▼
5d:
-14.64%
30d:
-20.45%
90d:
-9.59%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ATYR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATYR is down 14.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATYR is down 14.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATYR is currently trading at $0.43, which is considered oversold relative to its 30-day fair value range of $0.48 to $0.55.
Technical Outlook: Technically, ATYR is in a downtrend. The price is currently testing key support at $0.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ATYR scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.86 (+564.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATYR is in a downtrend. The price is currently testing key support at $0.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ATYR scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.86 (+564.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.48 -
$0.55
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 564.8% below Wall St target ($2.86)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.48 -
$0.55
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.42
Resistance Level
$0.57
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.91
Wall Street Target
$2.86
(+564.8%)
Share & Embed Analysis
Last updated: September 13, 2026 9:46 AM ET
Data refreshes hourly during market hours. Next update: 10:46 AM
Data refreshes hourly during market hours. Next update: 10:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATYR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
